Ślusarczyk, Rafał
Bielejewska, Ada
Bociek, Arkadiusz
Bociek, Martyna
2018-07-03
<p>Ceftaroline is a new fifth generation cephalosporin, active mostly against Gram-positive cocci, e.g. <em>Staphylococcus aureus</em> (including methicillin-resistant <em>Staphylococcus aureus</em>). It is used in treating acute bacterial skin and skin structure infections, community acquired respiratory tract infections and methicillin-resistant <em>S.</em> <em>aureus</em> bacteremia. The main resistance mechanisms of bacteria to β-lactam antibiotics, including ceftaroline, are mutations in PBP2a, PBP3 and PBP4. Clinically significant resistance has been noted among both archived and newly-isolated strains in a laboratory test using serial passages. Ceftaroline-resistant strains have also been found in patients suffering from cystic fibrosis, ventilator-associated pneumonia and infectious endocarditis. Irresponsible antibiotic treatment using ceftaroline or other antibiotics (due to a possibility of a cross-resistance) can lead to the spread of ceftaroline resistance and, consequently, its loss of value.</p>
https://doi.org/10.5281/zenodo.1304435
oai:zenodo.org:1304435
Zenodo
issn:2449-8955
https://doi.org/10.5281/zenodo.1304434
info:eu-repo/semantics/openAccess
Creative Commons Attribution Non Commercial 4.0 International
https://creativecommons.org/licenses/by-nc/4.0/legalcode
European Journal of Biological Research, 8(3), 112-120, (2018-07-03)
Antibiotic
Antibiotic resistance
MRSA
Resistant strains
Ceftaroline-resistant
Resistance to ceftaroline - 2018 review
info:eu-repo/semantics/article